Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation.
Areesha Moiz, Kristian B Filion, Michael A Tsoukas...
https://pubmed.ncbi.nlm.nih.gov/39892489/Actively Recruiting
Led by TC Erciyes University · Updated on 2026-09-03
60
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying adults with obesity to understand changes in anhedonia and emotional eating behaviors when starting treatment with glucagon-like peptide-1 GLP-1 receptor agonists for weight loss. This observational study focuses on how these medications, which affect appetite and reward-related brain areas, impact emotional and reward-related eating over time. Participants newly starting GLP-1 receptor agonist therapy are assessed at the beginning of treatment and again after six months. These assessments use standardized questionnaires to measure anhedonia with the Dimensional Anhedonia Rating Scale DARS and emotional eating patterns with the Emotional Eating Scale EES. The study also tracks treatment adherence, dosage changes, appetite variations, and any adverse effects. During the study, participants attend two main evaluation visits one at treatment start and another six months later. At these visits, researchers collect demographic information, questionnaire responses, and clinical data to monitor changes. The main outcome is the change in anhedonia scores over six months, with emotional eating changes as a secondary measure. The study is conducted at a single center and ends in December 2026.
CONDITIONS
Evaluation of Anhedonia and Emotional Eating in Individuals Using GLP-1 Receptor Agonists
H
Hasan Durmuş, MD, Assoc. Prof.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
TC Erciyes University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At treatment initiation
Participants complete questionnaires on anhedonia and emotional eating, and provide demographic and clinical information at the start of GLP-1 receptor agonist treatment.
1 visit (in-person)
Duration - 6 months after baseline
Participants complete follow-up questionnaires and provide information on treatment adherence, dosage, appetite changes, and side effects.
1 visit (in-person)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Areesha Moiz, Kristian B Filion, Michael A Tsoukas...
https://pubmed.ncbi.nlm.nih.gov/39892489/Hale Yapici-Eser, Vivek Appadurai, Candan Yasemin Eren...
https://pubmed.ncbi.nlm.nih.gov/32213216/TC Erciyes University
Lead Sponsor